Last month, Novo Nordisk claimed Wegovy could also reduce risk of cardiovascular events by 20%, as it announced headline findings from its SELECT trial, although they have not yet been published in a peer-reviewed journal
This effect is caused by semaglutide reprogramming immune cells and macrophages via the GLP-1R/PPARG/ACSL1 pathway, also causing anticancerous effects in rodents (9)
Various metabolites, such as lactate that is produced by tumour cells rely on the glycolytic pathway to reshape the homeostasis and metabolism of the microenvironment, resulting in higher lactate abundance
Available from: Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al